In short
This article discusses the clinical trials of STC-1010, an innovative immunotherapy drug being tested for patients with advanced or metastatic colorectal cancer. The BreAK CRC trial aims to evaluate the safety, efficacy, and optimal dosing of STC-1010 when combined with standard-of-care treatments. This study offers hope for patients with limited treatment options and may potentially improve outcomes for those battling this challenging form of cancer.
At a glance
- Drug Name
- STC-1010 (Stimulated Tumor Cells-1010)
- Trial Name
- BreAK CRC (BreAK for Brenus Anti-cancer)
- Trial Phase
- Phase I/IIA
- Target Condition
- Unresectable locally advanced or metastatic colorectal cancer
- Main Objectives
- Evaluate safety, determine optimal dose, assess clinical efficacy
- Treatment Combination
- STC-1010 with standard-of-care therapy (e.g., mFOLFOX6 + bevacizumab)
- Patient Groups
- MSS/pMMR and MSI-H/dMMR colorectal cancer patients
- Primary Endpoint
- Phase I: Safety profile; Phase IIA: Progression-free survival at 12 months
What is STC-1010?
STC-1010 is a new immunotherapy drug being developed to treat advanced or metastatic colorectal cancer. It's currently being studied in a clinical trial called the BreAK CRC trial. STC-1010 is also known as "Stimulated Tumor Cells-1010," which gives us a clue about how it works.
How Does STC-1010 Work?
STC-1010 is a type of treatment called cell therapy. It's made up of six different components, all derived from colorectal cancer cells: HCT116-A HCT116-B HT-29-A HT-29-B LOVO-A LOVO-B These components are designed to stimulate your immune system to fight against colorectal cancer cells in your body.
STC-1010 is given as an intradermal injection, which means it's injected just under the skin. This method helps to activate your immune system effectively.
Who Might Benefit from STC-1010?
STC-1010 is being studied for patients with: Unresectable locally advanced colorectal cancer: This means cancer that has spread locally but can't be completely removed with surgery. Metastatic colorectal cancer: This is cancer that has spread to other parts of the body. The trial is looking at two main groups of patients: Those with MSS (microsatellite stable) tumors who haven't had treatment before. Those with MSI-H (microsatellite instability-high) tumors, including Lynch syndrome, who have already tried immunotherapy but it didn't work.
The BreAK CRC Clinical Trial
The BreAK CRC trial is studying STC-1010 in combination with other cancer treatments. It has two main parts: Phase I: This part is testing different doses of STC-1010 to find the safest and most effective dose. Phase IIA: This part is looking at how well STC-1010 works in larger groups of patients.
In both phases, STC-1010 is given along with standard chemotherapy drugs (like FOLFOX) and other targeted therapies (like bevacizumab). The treatment is given in two stages: Induction treatment: Up to 8 cycles of more intense treatment. Maintenance treatment: Less intense treatment that continues for a longer time.
Eligibility for the Trial
To join the trial, patients need to meet certain criteria. Some key points include: Age 18-75 years Confirmed diagnosis of advanced or metastatic colorectal cancer Good overall health status No active autoimmune diseases No recent major surgery or radiation therapy There are many other specific criteria that your doctor would need to check.
Potential Benefits and Risks
The main goals of the STC-1010 treatment are to: Slow down or stop the growth of cancer Improve survival rates, especially for patients who haven't responded to other treatments Provide a new option for patients with advanced colorectal cancer
However, as with any new treatment, there may be risks and side effects. The trial is carefully monitoring patients for any adverse events. Some potential risks could include immune-related side effects, as STC-1010 works by stimulating the immune system.
It's important to remember that STC-1010 is still in the testing phase. More research is needed to fully understand its effectiveness and safety. If you're interested in this treatment, talk to your oncologist about whether you might be eligible for the clinical trial.